



For immediate release

Omron Healthcare India join hands with Lupin

For strategic collaboration on one-stop respiratory disease management facilities in India

New Delhi, June 12, 2020: Omron Healthcare India, a leading healthcare monitoring brand in the country, and Lupin Limited, a global pharma major, today announced a long-term strategic alliance to strengthen respiratory disease management facilities in India mainly focusing on Asthma and COPD patients.

Synergizing their vision of improving lives and contributing to a better society through utilization of innovative technology, the alliance aims to support the whole journey and experience of a respiratory patient right from diagnosis to treatment. Under this collaboration, the two companies will combine their respective strengths in disease know-how and solution-creation abilities to transform the outcomes of respiratory disease management by giving patients an ideal one-stop ecosystem providing screening, diagnostics, drug delivery, device, aided with advanced technology and digital tools all under one roof.

It is expected that the partnership will lead to:

- Development of a business model to broaden reach of disease management solutions and connect with un-diagnosed potential patients led by thought leadership and innovative expertise of both companies. This comprises setting up India's first-of-its-kind Nebulization Rooms in hospitals.
- Development of comprehensive and unique disease management solutions (drugs & devices) for optimal treatment; utilizing advanced sensing technologies such as WheezScan - India's first device to monitor wheezing in children and Mesh Nebulizers for accurate drug delivery.

In response to signing the MoU with OMRON, Rajeev Sibal, President – India Region Formulations, Lupin Limited, mentioned LUPIN's long association with OMRON, a global leader in healthcare monitoring, and expressed confidence that this MoU will usher a new era in terms of improving awareness, diagnosis, adherence & drug delivery, all of which are focus areas for the respiratory team. He added that devices & initiatives under this MoU will help the clinicians to significantly improve clinical outcomes and boost the quality of life of patients.



Elaborating more, Mr. Masanori Matsubara, MD, OMRON Healthcare India, said “This joint endeavor with Lupin is one of the most significant steps in the direction of achieving OMRON’s ‘Zero Asthma Events’ vision for Indian society. We are extremely hopeful & confident that our expertise in technology & monitoring will synergize well with Lupin’s capabilities in pharmaceuticals to create a new business model strongly oriented towards creating value in the lives of millions of people suffering from debilitating diseases like asthma and COPD.”

...

About OMRON Healthcare India:

Established in 2010, OMRON Healthcare India is a key player in the health care segment providing innovative medical technologies for Monitoring and Therapy. Equipped with OMRON's competent "Bio-information Sensing" the portfolio comprises of home healthcare products such as blood pressure monitors, respiratory therapy devices, body fat monitors, digital thermometers, pain management devices, etc. OMRON Healthcare was the first to introduce manual and digital blood pressure units to the home healthcare market in the world. Today, OMRON has the highest market share in the home-use digital BP monitor in India and across the globe.

To learn more, please visit:

<https://www.omronhealthcare-ap.com/in>;

<https://www.omronbrandshop.com/>



About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/



For more details, please contact :

Ankur Bhat(Ms.) , ankur.bhat@omron.com, 9899819904